First of all, they indicated that the levels of ghrelin should have been presented as 100-150 fmol/ml. However, we analyzed full-length octanoylated human ghrelin using a commercial radioimmunoassay (RIA) kit (Phoenix Pharmaceuticals Inc., Phoenix, AZ, USA) and the results were expressed as pg/ml. Several studies have used this kit and they also reported serum ghrelin levels in a wide range as 60-493 pg/ml, 119.6-827.8 pg/ml and 347-1260 pg/ml, respectively. [2] [3] [4] Measurements done in the morning at fasting state and serums obtained from the antecubital vein were kept at À80 8C until analysis, as mentioned in 'Material and Method' section of the paper. The values determined in the study are not at very low levels as alleged by the Suleyman Aydin. Secondly, he claimed that the patients in the epilepsy group might become obese and this might lead to controversy about the results. Nonetheless, when the material and methods of our study are read carefully, it can be seen that all study groups including the epilepsy group that were taking AED had a BMI less than 25. An increase in bodyweight may occur in patients taking AED, however, this was not the case for all the patients.
Our study population consisted of epilepsy patients without any body weight-gain due to medication, which makes the argument of Suleyman Aydin invalid.
Lastly, the ghrelin values presented in our study are full-length octanoylated human ghrelin levels.
The two values of ghrelin measurements indicated in the material and method section are the result of two different values measured by the kit. Additionally, the value presented in the study indicates the active biopeptide levels.
